Tag: Multiple Myeloma

Targeted Drugs and Immunotherapies May Lower Risk of Therapy-Related Hematologic Cancers

sarah JonasResearch Results

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.

Immune system changes occur early in development of multiple myeloma, study finds

sarah JonasResearch Results

Long before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergoes dramatic shifts, with alterations in both the number and type of immune cells, researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital (MGH) report in a new study.

New Mayo Clinic studies to be presented at American Society of Hematology meeting

sarah JonasResearch Results

Mayo Clinic researchers will present findings at the American Society of Hematology Annual Meeting Dec. 7–10 in Orlando.
New Mayo Clinic studies to be presented include:
DNA analysis identifies elevated risk factor for myeloma in individuals of African ancestry
Study identifies more precise assessment measures for patients newly diagnosed with chronic lymphocytic leukemia
Researchers develop method to assess cancer-fighting cell therapy’s effectiveness

Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting

sarah JonasResearch Results

Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.

New NCCN Guidelines Debut to Manage Complications and Improve Readiness for Stem Cell Transplant Recipients

sarah JonasAnnouncement

The National Comprehensive Cancer Network (NCCN) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation, (aka stem cell transplant or bone marrow transplant), with step-by-step information on best practices for this blood cancer treatment